Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Dec 01, 2010 (Vol. 30, No. 21)

The Cancer Genome Atlas

  • Nice web design, detailed search parameters
  • No online browser/preview; datasets must be downloaded and e-mailed

First, I must award major points to The Cancer Genome Atlas for creating a name whose acronym reads as a DNA sequence (TCGA). Bravo! Looking beyond the acronym, The Cancer Genome Atlas is an initiative launched by the National Cancer Institute and the National Human Genome Research Institute that aims to utilize genome analysis technologies to improve our understanding of the molecular basis of cancer. The fruits of this endeavor can be accessed through the Data Portal, which allows researchers to search and download datasets generated by the researchers with The Cancer Genome Atlas. Within the Data Portal, 10 different cancer types are represented, and visitors can choose to search either by cancer type or by genes, participants, or pathways. My biggest complaint about the site is the fact that one must download the datasets, rather than browse them online. Downloaded files must be e-mailed to the user, and they are then available on the server for 24 hours.

  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »